Gyre Therapeutics, Inc.
As of Oct 22, 2026, Gyre Therapeutics is in Stage 1, the basing phase, now in week 10 (since Aug 19, 2026). It closed at $5.86, 33.1% below its 52-week high and below its 200-day average, which is falling.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is GYRE early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
GYRE among Biotechnology275th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …275 | GYRE | Stage 1 · wk 10 | 34 | −20.8% |
Gyre Therapeutics: quick answers
What stage is Gyre Therapeutics in?
As of Oct 22, 2026, Gyre Therapeutics (GYRE) is in Stage 1, the basing phase. It entered Stage 1 on Aug 19, 2026 and is in week 10. What the four stages mean
Is Gyre Therapeutics in an uptrend?
Not yet. Gyre Therapeutics is in Stage 1, a base that can come before an uptrend. It trades 16.7% below its 200-day average, which is falling.
How far is Gyre Therapeutics from its 52-week high?
Gyre Therapeutics closed at $5.86 on Oct 22, 2026, 33.1% below its 52-week high of $8.76. Its 52-week low is $5.56.
How has Gyre Therapeutics performed over the past year?
As of Oct 22, 2026, Gyre Therapeutics is down 29.6% over the past year and down 14.0% so far in 2026.
Which sector and industry is Gyre Therapeutics in?
Gyre Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.